OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
63 hedge funds and large institutions have $44.4M invested in OncoMed Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 9 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 17
5% less funds holding
Funds holding: 66 → 63 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
27% less capital invested
Capital invested by funds: $61M → $44.4M (-$16.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$959K |
| 2 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$320K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$238K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$234K |
| 5 |
BP
BBR Partners
New York
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$740K |
| 2 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$458K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$447K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$217K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$180K |
OMED Hedge Fund Activity: Q2 2018 in Review
63 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2018, worth a combined $44.4M — down 27% from $61M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of OMED and 7 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 23 added.
The largest buyer was Sofinnova Investments, adding an estimated $959K. The largest seller was Millennium Management, exiting entirely with an estimated $740K sold.
- 63 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2018, down from 66 in Q1 2018.
- Funds reported $44.4M of OncoMed Pharmaceuticals, Inc. stock for Q2 2018, down 27% quarter-over-quarter.
- 7 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2018 and 9 closed out, a net change of -2 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q2 2018 was Sofinnova Investments, an estimated $959K added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2018 was Millennium Management, an estimated $740K sold.
Based on aggregated 13F filings for Q2 2018.